Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Urinary Tract Clear all
Completed Phase 1 Interventional

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

NCT00019435
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer
Interventions
LMB-9 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 25, 2026, 6:03 AM EDT
Completed Not applicable Interventional

VeSpAR: Comparing Vessel-Sparing Anastomotic Repair and Transecting Anastomotic Repair in Isolated Short Bulbar Strictures.

NCT03572348
View directory record Official record
Conditions
Urethral Stricture, Surgery, Urologic Diseases
Interventions
Transecting anastomotic repair (tAR), Vessel-sparing anastomotic repair (vsAR)
Procedure
Lead sponsor
University Hospital, Ghent
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Syracuse, New York • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2024 · Synced Sep 25, 2026, 6:03 AM EDT
Recruiting Not applicable Interventional

Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting

NCT06976125
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Decision Aid-prediction model
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 25, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Patients With Nocturia (Non-PK Study)

NCT00937378
View directory record Official record
Conditions
Nocturia
Interventions
SER120, Placebo
Drug
Lead sponsor
Serenity Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 25, 2026, 6:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of a Prepackaged Cleansing Cloth and Standardized Cleansing Protocol for Catheter Care at Reducing CAUTI Rates

NCT03645967
View directory record Official record
Conditions
Catheter-Associated Urinary Tract Infection
Interventions
ReadyCleanse Cloths
Device
Lead sponsor
Medline Industries
Industry
Eligibility
18 Years and older
Enrollment
9,891 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
Evanston, Illinois • Glenview, Illinois • Highland Park, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 25, 2026, 6:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder Symptoms

NCT00771264
View directory record Official record
Conditions
Overactive Bladder
Interventions
Urgent PC Neuromodulation System
Device
Lead sponsor
Uroplasty, Inc
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
15
States / cities
Chico, California • Greenwich, Connecticut • Naples, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Sep 25, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

NCT03492281
View directory record Official record
Conditions
Overactive Bladder
Interventions
vibegron, Vibegron placebo, Tolterodine Tartrate ER, Tolterodine placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
191
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 155 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Sep 25, 2026, 6:03 AM EDT
Withdrawn Not applicable Interventional

A Yoga Program for Patients Undergoing Prostate Cancer Surgery

NCT05929300
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction, Urinary Incontinence
Interventions
Yoga, Usual Care
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 25, 2026, 6:03 AM EDT
Completed Phase 4 Interventional Results available

Procedural Discomfort Related to Number of Intradetrusor Botox Injections

NCT05652036
View directory record Official record
Conditions
Overactive Bladder
Interventions
Intradetrusor Botox Injections
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Sep 25, 2026, 6:03 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Lactobacillus Probiotic for Prevention of UTI

NCT03151967
View directory record Official record
Conditions
Urinary Tract Infections (UTI's)
Interventions
Lactobacillus crispatus CTV-05, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 25, 2026, 6:03 AM EDT
Not listed Phase 1 Interventional

Bacteriuria Eradication Through Probiotics

NCT00717600
View directory record Official record
Conditions
Bacteriuria
Interventions
Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 18 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2008 · Synced Sep 25, 2026, 6:03 AM EDT
Recruiting Phase 2 Interventional

CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury

NCT06840899
View directory record Official record
Conditions
Supra-sacral Spinal Cord Injury, Spinal Cord Injury, Urinary Incontinence
Interventions
CBD
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 25, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Randomized Control Trial to Assess Postoperative Pain After Sling Placement

NCT00746863
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
0.125% Marcaine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2010 · Synced Sep 25, 2026, 6:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Intravesical Gentamicin to Prevent Recurrent UTI

NCT06332781
View directory record Official record
Conditions
Recurrent Uti
Interventions
Gentamicin, Nitrofurantoin
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
40 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 25, 2026, 6:03 AM EDT
Completed Not applicable Interventional

Effects of Flourish on Recurrent Urinary Tract Infection

NCT05397782
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
BioNourish, a component of Flourish HEC
Device
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Sep 25, 2026, 6:03 AM EDT
Not listed Not applicable Interventional

Importance of Patient Positioning at Cough Test When Considering Success Following Sling Procedures

NCT03120117
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Cough Test following Sling Surgery
Procedure
Lead sponsor
Michigan Institution of Women's Health PC
Other
Eligibility
21 Years to 89 Years · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Sep 25, 2026, 6:03 AM EDT
Active, not recruiting Phase 2 Interventional

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

NCT05111574
View directory record Official record
Conditions
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Urinary System Mucosal Melanoma, Vaginal Melanoma, Vulvar Melanoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nivolumab, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
142
States / cities
Auburn, California • Berkeley, California • Fremont, California + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 25, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

NCT00611026
View directory record Official record
Conditions
Overactive Bladder
Interventions
Tolterodine ER, Placebo, Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
102
States / cities
Enterprise, Alabama • Mobile, Alabama • Montgomery, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2011 · Synced Sep 25, 2026, 6:03 AM EDT
Recruiting Phase 2 Interventional

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

NCT06822010
View directory record Official record
Conditions
Urinary Bladder Cancer, Upper Tract Urothelial Cancer, Urothelial Cancer
Interventions
Sequential Gemcitabine and Jelmyto Treatment (Gem/Jel)
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 25, 2026, 6:03 AM EDT
Completed Not applicable Interventional

An Educational Video to Improve Patient Comprehension of Midurethral Sling

NCT03808974
View directory record Official record
Conditions
Stress Urinary Incontinence, Knowledge, Attitudes, Practice
Interventions
Educational video, Educational leaflet
Other
Lead sponsor
Felicia Lane
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 25, 2026, 6:03 AM EDT
Completed Not applicable Interventional

Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms

NCT04758247
View directory record Official record
Conditions
Overactive Bladder
Interventions
TheraNova Neuromodulation System
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Sacramento, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 25, 2026, 6:03 AM EDT
Not listed Not applicable Interventional

Optimal Injection Interval for Intra-Detrusor Botulinum Toxin

NCT06483217
View directory record Official record
Conditions
Overactive Bladder, Urinary Urgency, Urinary Incontinence, Urge Urinary Incontinence
Interventions
Patient-directed follow up
Behavioral
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 25, 2026, 6:03 AM EDT
Recruiting Not applicable Interventional

Aquarius Pilot Study to Evaluate the New Axonics Trial System

NCT07335484
View directory record Official record
Conditions
Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI), Overactive Bladder (OAB)
Interventions
Axonics External Trial System (ETS)
Device
Lead sponsor
Axonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 25, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

NCT01599806
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 25, 2026, 6:03 AM EDT